We have developed and patented a Baculovirus Expression Vector System (BEVS) that we use in all of our products and services. This platform leverages the natural infection process of insect cells by baculoviruses. We re-engineer the baculovirus such that it programs the infected insect cells to generate large quantities of desired recombinant protein(s). Our proprietary expresSF+ cell line has been optimized for this purpose. The end result is the production of large amounts of pure protein, generated more quickly and less expensively than other production systems.
We have created and patented a unique Spodoptera frugiperda insect cell line, expresSF+ cells, to optimize protein production using our BEVS technology. These cells have been extensively characterized and products manufactured from them have received regulatory clearance for human clinical testing in the United States, Japan, Australia, Europe, Canada and elsewhere. A veterinary PCV-2 vaccine produced in our cells is being marketed worldwide, including in the United States, Europe and Japan.
Uninfected expresSF+ cells
AcNPV infected expresSF+ cells
expresSF+ Advantages:
FDA-qualified
Serum-free, low cost growth media
High density growth and gene expression capability
Produces high titer AcNPV (108 PFU/ml)
Infected with low MOI
Stable for > 50 passages
18-24 hour doubling time
Do not clump or aggregate
Scalable for cGMP manufacturing
Our expresSF+ cell line has been characterized and qualified for:
Identity and stability
Freedom of mycoplasma, spiroplasma and other adventitious organism contamination
Freedom of retrovirus-like particles
Non-tumorgenicity in mice
Serum-free:
expresSF+ cells do not require serum for growth or storage, and double about every 24 hours in our proprietary serum-free media. Unlike other serum-free insect cells, expresSF+ cells generate high titers of baculovirus. Therefore, a single cell line can be used for production of large quantities of protein.
High density:
expresSF+ cells can be grown to a density of 108 cells/ml. At a density of 107 cells/ml, the cells are nearly 100% viable in standard suspension cultures. We have established and patented high density fermentation and fed-batch procedures to maximize protein yield. Under these conditions, cell growth is exponential from 1.5X106 to more than 70X106 cells/ml in serum-free media, and viability remains at least 98%.
Licensing agreements are available to use our expresSF+ cells. Please contact Daniel Adams, Executive Chairman and Global Head of Business Development, at 1-203-686-0800 x303.
Low-cost, rapid production of proteins
